Trade Galectin Therapeutics Inc. - GALT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0400 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.235 |
| Open | 1.22 |
| 1-Year Change | -49.3% |
| Day's Range | 1.22 - 1.325 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 1.2350 | 0.0250 | 2.07% | 1.2100 | 1.2800 | 1.1900 |
| Mar 31, 2025 | 1.2050 | -0.0350 | -2.82% | 1.2400 | 1.3500 | 1.1600 |
| Mar 28, 2025 | 1.4950 | -0.1950 | -11.54% | 1.6900 | 1.6900 | 1.4950 |
| Mar 27, 2025 | 1.6450 | -0.0050 | -0.30% | 1.6500 | 1.6850 | 1.5500 |
| Mar 26, 2025 | 1.6150 | -0.0850 | -5.00% | 1.7000 | 1.8100 | 1.6100 |
| Mar 25, 2025 | 1.7550 | 0.1650 | 10.38% | 1.5900 | 1.7750 | 1.5900 |
| Mar 24, 2025 | 1.6250 | 0.0850 | 5.52% | 1.5400 | 1.6250 | 1.4700 |
| Mar 21, 2025 | 1.5350 | 0.0250 | 1.66% | 1.5100 | 1.5550 | 1.4450 |
| Mar 20, 2025 | 1.5150 | -0.0250 | -1.62% | 1.5400 | 1.5750 | 1.4900 |
| Mar 19, 2025 | 1.5450 | -0.0450 | -2.83% | 1.5900 | 1.5900 | 1.4750 |
| Mar 18, 2025 | 1.5650 | -0.0050 | -0.32% | 1.5700 | 1.5800 | 1.5350 |
| Mar 17, 2025 | 1.5850 | -0.0550 | -3.35% | 1.6400 | 1.6700 | 1.4800 |
| Mar 14, 2025 | 1.6550 | -0.0150 | -0.90% | 1.6700 | 1.7450 | 1.6250 |
| Mar 13, 2025 | 1.7450 | 0.0650 | 3.87% | 1.6800 | 1.7750 | 1.6400 |
| Mar 12, 2025 | 1.6850 | 0.1550 | 10.13% | 1.5300 | 1.6900 | 1.5300 |
| Mar 11, 2025 | 1.5750 | -0.0150 | -0.94% | 1.5900 | 1.6200 | 1.5300 |
| Mar 10, 2025 | 1.5750 | 0.0050 | 0.32% | 1.5700 | 1.6250 | 1.5500 |
| Mar 7, 2025 | 1.5950 | 0.0250 | 1.59% | 1.5700 | 1.6150 | 1.5200 |
| Mar 6, 2025 | 1.5750 | -0.0150 | -0.94% | 1.5900 | 1.6150 | 1.5300 |
| Mar 5, 2025 | 1.5500 | 0.0300 | 1.97% | 1.5200 | 1.6050 | 1.5200 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Galectin Therapeutics Inc. Company profile
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).
Equity composition
Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com